Eine Studie zur individuellen Anpassung von Ibrutinib-Behandlungsschemata für Teilnehmer mit zuvor unbehandelter chronischer lymphatischer Leukämie (TAILOR)
Multikohortenstudie zur individuellen Anpassung von Ibrutinib-Behandlungsschemata für Patienten mit zuvor unbehandelter chronischer lymphatischer Leukämie
The purpose of this study is to evaluate the efficacy and safety of ibrutinib + venetoclax (I+V) and ibrutinib monotherapy regimens in which dosing of ibrutinib is either proactively reduced or reactively modified in response to adverse events (AEs).
Studienübersicht
Status
Intervention / Behandlung
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 2
Kontakte und Standorte
Studienorte
-
-
-
Clermont-Ferrand, Frankreich, 63100
- CHU de Clermont Ferrand
-
Nantes, Frankreich, 44000
- CHU Nantes
-
Paris, Frankreich, 75651
- Hopital Pitie Salpetriere
-
Pierre-Bénite, Frankreich, 69495
- CHU Lyon Sud
-
Reims, Frankreich, 51100
- CHU de Reims
-
Strasbourg, Frankreich, 67200
- Institut de Cancerologie Strasbourg Europe ICANS
-
-
-
-
-
Bari, Italien, 70124
- U.O. Ematologia Istituto Tumori Giovanni Paolo II
-
Ferrara, Italien, 44124
- Azienda Ospedaliero-Universitaria di Ferrara Arcispedale Sant Anna
-
Florence, Italien, 50134
- Azienda Ospedaliero Universitaria Careggi
-
Milan, Italien, 20132
- Ospedale San Raffaele
-
Milan, Italien, 20162
- ASST Grande Ospedale Metropolitano Niguarda
-
Novara, Italien, 28100
- Ospedale Maggiore della Carita
-
Padova, Italien, 35129
- Universita degli Studi di Padova Azienda Ospedaliera di Pa
-
Palermo, Italien, 90146
- Ospedale Villa Sofia-Cervello
-
Perugia, Italien, 06132
- Azienda Ospedaliera di Perugia Ospedale S.Maria della Misericordia
-
Roma, Italien, 00161
- Umberto I Policlinico di Roma
-
Roma, Italien, 00136
- Ematologia Fondazione Univ. Policlinico Gemelli Università Cattolica del Sacro Cuore
-
-
-
-
Nova Scotia
-
Halifax, Nova Scotia, Kanada, B3H 1V7
- QEII Health Sciences Centre
-
-
Ontario
-
St. Catharines, Ontario, Kanada, L2S 0A9
- Niagara Health System
-
-
-
-
-
Biała Podlaska, Polen, 21 500
- Wojewodzki Szpital Specjalistyczny
-
Brzozów, Polen, 36 200
- Szpital Specjalistyczny w Brzozowie
-
Gdynia, Polen, 81-519
- Szpitale Pomorskie Sp z o o
-
Kielce, Polen, 25 734
- Swietokrzyskie Centrum Onkologii SPZOZ w Kielcach
-
Krakow, Polen, 30 688
- Samodzielny Publiczny Zaklad Opieki Zdrowotnej Szpital Uniwersytecki w Krakowie
-
Lodz, Polen, 93 513
- Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im M Kopernika w Lodzi
-
Lublin, Polen, 20 090
- Centrum Onkologii Ziemi Lubelskiej im sw Jana z Dukli
-
-
-
-
-
Barcelona, Spanien, 08035
- Hosp Univ Vall D Hebron
-
Córdoba, Spanien, 14004
- Hosp Reina Sofia
-
Madrid, Spanien, 28041
- Hosp. Univ. 12 de Octubre
-
Madrid, Spanien, 28034
- Hosp. Univ. Ramon Y Cajal
-
Santander, Spanien, 39008
- Hosp. Univ. Marques de Valdecilla
-
Santiago de Compostela, Spanien, 15706
- Hosp. Clinico Univ. de Santiago
-
-
-
-
-
Brno-Bohunice, Tschechien, 625 00
- Fakultni nemocnice Brno
-
Hradec Králové, Tschechien, 500 05
- Fakultni nemocnice Hradec Kralove
-
Olomouc, Tschechien, 779 00
- Fakultni nemocnice Olomouc
-
Ostrava - Poruba, Tschechien, 708 52
- Fakultni Nemocnice Ostrava
-
Prague, Tschechien, 100 34
- Fakultni nemocnice Kralovske Vinohrady
-
Prague, Tschechien, 128 00
- Ustav Hematologie A Krevni Transfuze
-
-
-
-
-
Budapest, Ungarn, 1088
- Semmelweis Egyetem
-
Győr, Ungarn, 9024
- Gyor Moson Sopron Varmegyei Petz Aladar Egyetemi Oktato Korhaz
-
Nyíregyháza, Ungarn, 4400
- Szabolcs Szatmar Bereg Varmegyei Oktatokorhaz
-
Szeged, Ungarn, 6725
- University of Szeged
-
-
-
-
California
-
Cerritos, California, Vereinigte Staaten, 90703
- The Oncology Institute Clinical Research
-
Los Alamitos, California, Vereinigte Staaten, 90720
- Cancer and Blood Specialty Clinic
-
San Luis Obispo, California, Vereinigte Staaten, 93401
- SLO Oncology and Hematology Health Center
-
Santa Rosa, California, Vereinigte Staaten, 95403
- Providence Medical Foundation
-
Whittier, California, Vereinigte Staaten, 90602
- PIH Health Hospital
-
-
Colorado
-
Grand Junction, Colorado, Vereinigte Staaten, 81505
- Grand Valley Oncology
-
-
Florida
-
Miami Beach, Florida, Vereinigte Staaten, 33140-2948
- Mount Sinai Medical Center Campus
-
North Miami Beach, Florida, Vereinigte Staaten, 33169
- The Oncology Institute
-
Orange, Florida, Vereinigte Staaten, 32763
- Mid Florida Hematology Oncology
-
-
Idaho
-
Boise, Idaho, Vereinigte Staaten, 83702
- Boise VA Medical Center
-
-
Illinois
-
Hinsdale, Illinois, Vereinigte Staaten, 60521
- Hope and Healing Cancer Services
-
Springfield, Illinois, Vereinigte Staaten, 62702
- Springfield Clinic
-
-
Iowa
-
Iowa City, Iowa, Vereinigte Staaten, 52246
- Iowa City VA Health Care System
-
-
Minnesota
-
Minneapolis, Minnesota, Vereinigte Staaten, 55404
- Minnesota Oncology Hematology P A
-
-
Missouri
-
Kansas City, Missouri, Vereinigte Staaten, 64132
- Research Medical Center
-
-
New Jersey
-
Flemington, New Jersey, Vereinigte Staaten, 08822
- Hunterdon Hematology Oncology
-
Florham Park, New Jersey, Vereinigte Staaten, 07932
- Summit Medical Group
-
-
New York
-
Nyack, New York, Vereinigte Staaten, 10960
- Hematology Oncology Associates of Rockland
-
-
North Carolina
-
Goldsboro, North Carolina, Vereinigte Staaten, 27534
- Southeastern Medical Oncology Center
-
-
Ohio
-
Cincinnati, Ohio, Vereinigte Staaten, 45242
- Oncology Hematology Care
-
-
Oregon
-
Eugene, Oregon, Vereinigte Staaten, 97401
- Willamette Valley Cancer Institute and Research Center
-
Portland, Oregon, Vereinigte Staaten, 97239
- OHSU Knight Cancer Institute
-
-
Texas
-
El Paso, Texas, Vereinigte Staaten, 79915
- Renovatio Clinical
-
Fort Worth, Texas, Vereinigte Staaten, 76104
- Texas Oncology-Fort Worth Cancer Center
-
Houston, Texas, Vereinigte Staaten, 77030
- The University of Texas MD Anderson Cancer Center
-
The Woodlands, Texas, Vereinigte Staaten, 77380
- Renovatio Clinical 1
-
The Woodlands, Texas, Vereinigte Staaten, 77380
- Texas Oncology-Gulf Coast
-
-
Utah
-
Ogden, Utah, Vereinigte Staaten, 84405
- Community Cancer Trials of Utah
-
-
Virginia
-
Manassas, Virginia, Vereinigte Staaten, 20110
- Virginia Cancer Specialists
-
Virginia Beach, Virginia, Vereinigte Staaten, 23456
- Virginia Oncology Associates
-
-
Washington
-
Seattle, Washington, Vereinigte Staaten, 98108
- VA Puget Sound Healthcare System
-
Vancouver, Washington, Vereinigte Staaten, 98684
- Northwest Cancer Specialists PC
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Diagnosis of chronic lymphocytic leukemia/ small lymphocytic lymphoma (CLL/SLL) as per International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2018 diagnostic criteria
- For ibruinib + venetocIax (I+V) cohorts: eastern cooperative oncology group (ECOG) performance status of 0-1. For ibrutinib monotherapy cohorts: ECOG performance status of 0-2
- Measurable nodal disease by computed tomography (CT), defined as at least 1 lymph node greater than and equal to (>=) 1.5 centimeters (cm) in longest diameter
- A participant using oral contraceptives must use an additional contraceptive method
- A participant must agree not to be pregnant, breastfeeding, or planning to become pregnant while enrolled in this study or until 1 month after last dose or per local label if more conservative (for example, 3 months in European Union or Canada and 1 month in United States)
Exclusion Criteria:
- Uncontrolled autoimmune hemolytic anemia or idiopathic thrombocytopenia purpura, such as those participants with a declining hemoglobin level or platelet count secondary to autoimmune destruction within the 4 weeks prior to first dose of study treatment, or the need for prednisone greater than (>) 20 milligrams (mg) daily (or corticosteroid equivalent) to treat or control the autoimmune disease
- Known bleeding disorders (example, von Willebrand's disease or hemophilia)
- Stroke or intracranial hemorrhage within 6 months prior to enrollment
- Known or suspected Richter's transformation or central nervous system (CNS) involvement
- Currently active, clinically significant cardiovascular disease, such as uncontrolled arrhythmia or Class II, III, or IV congestive heart failure as defined by the New York Heart Association Functional Classification
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Cohort 1a: Ibrutinib Lead-in+Fixed Duration Ibrutinib+Venetoclax
Participants will receive ibrutinib 420 milligrams (mg) capsule every day (QD) for a lead-in of 3 cycles (1 cycle = 28 days). From Cycle 4, venetoclax 400 mg tablet dose ramp-up (from 20 to 400 mg over 5 weeks) will begin, and venetoclax 400 mg QD will be administered with ibrutinib 420 mg QD, orally for 12 cycles through Cycle 15. |
Ibrutinib capsules will be administered orally.
Andere Namen:
Venetoclax tablets will be administered orally.
Andere Namen:
|
|
Experimental: Cohort 1b: Ibrutinib Lead-in+Fixed Duration Ibrutinib+Venetoclax
Participants will receive ibrutinib 420 mg capsule QD for a lead-in of 3 cycles (1 cycle = 28 days). From Cycle 4, venetoclax 400 mg tablet dose ramp-up (from 20 to 400 mg over 5 weeks) will begin and ibrutinib dose will be reduced to 280 mg and will be administered QD, venetoclax 400 mg tablets QD will be administered with ibrutinib 280 mg for 12 cycles through Cycle 15. |
Ibrutinib capsules will be administered orally.
Andere Namen:
Venetoclax tablets will be administered orally.
Andere Namen:
|
|
Experimental: Cohort 2a: Continuous Ibrutinib Monotherapy
Participants will receive ibrutinib 420 mg QD (or last tolerated dose) until disease progression (PD) or unacceptable toxicity. |
Ibrutinib capsules will be administered orally.
Andere Namen:
|
|
Experimental: Cohort 2b: Continuous Ibrutinib Monotherapy
Participants will receive ibrutinib 420 mg QD for 1 cycle (1 cycle = 28 days) followed by Ibrutinib 280 mg QD (or last tolerated dose) and continue until disease progression or unacceptable toxicity. |
Ibrutinib capsules will be administered orally.
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Best Overall Response Rate (ORR)
Zeitfenster: Up to 5 years
|
Best ORR is defined as the percentage of participants who achieve complete remission (CR), complete remission with an incomplete marrow recovery (CRi), nodular partial remission (nPR), or partial remission (PR) per International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2018 criteria as assessed by investigator. |
Up to 5 years
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Complete Response (CR) Rate
Zeitfenster: Up to 5 years
|
CR rate is defined as the percentage of participants achieving a best overall response of CR or CRi per iwCLL 2018 criteria as assessed by investigator. |
Up to 5 years
|
|
Duration of Response (DOR)
Zeitfenster: Up to 5 years
|
DOR is defined as the duration in days from the date of initial documentation of PR or better to the date of first documented evidence of PD or death. |
Up to 5 years
|
|
Progression Free Survival (PFS)
Zeitfenster: Up to 5 years
|
PFS by investigator assessment is defined as the duration from date of randomization to date of PD or death due to any cause, whichever occurs first. |
Up to 5 years
|
|
Overall Survival (OS)
Zeitfenster: Up to 5 years
|
OS is defined as the time from date of randomization to date of death from any cause. |
Up to 5 years
|
|
Cohorts 1a and 1b: Minimal Residual Disease (MRD) Negative Rate
Zeitfenster: Up to 5 years
|
MRD-negative rate is defined as the percentage of participants who reach MRD-negative status (that is, less than [<] 1 chronic lymphocytic leukemia (CLL) cell per 10,000 leukocytes or <0.01 percentage [%]) in the peripheral blood. |
Up to 5 years
|
|
Number of Participants with Adverse Events (AEs)
Zeitfenster: Up to 5 years
|
An adverse event (AE) is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. |
Up to 5 years
|
|
Number of Participants with AEs by Severity
Zeitfenster: Up to 5 years
|
An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening and Grade 5= Death related to adverse event. |
Up to 5 years
|
|
Percentage of Participants with Rate of Discontinuation due to AEs
Zeitfenster: Up to 5 years
|
Percentage of participants with rate of discontinuation due to AEs will be reported. |
Up to 5 years
|
|
Percentage of Participants with Dose Reduction due AEs
Zeitfenster: Up to 5 years
|
Percentage of participants with dose reduction due AEs will be reported. |
Up to 5 years
|
|
Adherence Rates
Zeitfenster: Up to 5 years
|
The adherence rate is defined as the percentage of total dose taken over the total dose prescribed. |
Up to 5 years
|
|
Duration of Treatment
Zeitfenster: Up to 5 years
|
Duration of treatment is defined as the time period in days between the date of first study treatment administration and date of last administration. |
Up to 5 years
|
|
Time to Worsening as Measured by EuroQol 5 Dimension 5 Level Questionnaire (EQ-5D-5L)
Zeitfenster: Up to 5 years
|
Time to worsening is defined as time interval (months) from randomization to first observation of deterioration. Time to worsening as measured by EQ-5D-5L will be reported. |
Up to 5 years
|
|
Time to Worsening as Measured by European Organization for Research and Treatment of Cancer-Quality of Life Questionnaire (EORTC QLQ)-C30)
Zeitfenster: Up to 5 years
|
Time to worsening is defined as time interval from randomization to first observation of deterioration. Time to worsening as measured by EORTC QLQ-C30 will be reported. |
Up to 5 years
|
|
Time to Worsening as Measured by EORTC QLQ-CLL17
Zeitfenster: Up to 5 years
|
Time to worsening is defined as time interval from randomization to first observation of deterioration. Time to worsening as measured by EORTC QLQ-CLL17 will be reported. |
Up to 5 years
|
|
Time to Worsening as Measured by Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Total Score
Zeitfenster: Up to 5 years
|
Time to Worsening is defined as time interval (months) from randomization to first observation of deterioration. Time to worsening as measured by FACIT-fatigue total score will be reported. |
Up to 5 years
|
Mitarbeiter und Ermittler
Mitarbeiter
Ermittler
- Studienleiter: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Pathologische Prozesse
- Neubildungen
- Chronische Erkrankung
- Krankheitsattribute
- Erkrankungen des Immunsystems
- Neubildungen nach histologischem Typ
- Hämatologische Erkrankungen
- Lymphatische Erkrankungen
- Lymphoproliferative Erkrankungen
- Immunproliferative Erkrankungen
- Leukämie, B-Zell
- Leukämie, lymphatisch
- Leukämie
- Pathologische Zustände, Anzeichen und Symptome
- Hämische und lymphatische Krankheiten
- Leukämie, lymphozytär, chronisch, B-Zell
- Venetoklax
- Ibrutinib
Andere Studien-ID-Nummern
- 54179060CLL2032
- 54179060CLL2032 (Andere Kennung: Janssen Research & Development, LLC)
- 2023-504044-34-00 (Registrierungskennung: EUCT number)
- 2023 (US NIH Stipendium/Vertrag)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .